Ergoline derivatives
AssigneeNovartis AG
InventorsRolf Baenteli, Fraser Glickman, Jiri Kovarik, Ian Lewis, Markus Streiff, Gebhard Thoma, Hans-Günter Zerwes
Life of this patent
Estimating the term…
Loading patent…
AssigneeNovartis AG
InventorsRolf Baenteli, Fraser Glickman, Jiri Kovarik, Ian Lewis, Markus Streiff, Gebhard Thoma, Hans-Günter Zerwes
Estimating the term…
Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or -phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C1-4alkyl; optionally R10 and/or R11-substituted heteroaryl N-oxide; optionally R10-substituted C1-C8 alkyl; optionally R10-substituted C2-C8 alkenyl, optionally R10-substituted C2-C8 alkynyl; optionally R10-substituted C3-C8 cycloalkyl, or optionally R10-substituted C4-C8 cycloalkenyl; or R1 and R2 form together with the nitrogen atom to which they are attached an optionally R10-substituted 3-8 membered ring containing in addition to the nitrogen atom up to 2 heteroatoms selected independently from N, O and S; R3 is H; OR1; CH2R1R2; (CH2)1-2NR1R2; CH2—CH2—OR1; CH2—CO—NR1R2; or CO—CH2R1R2; R4 is F; Cl; Br; I; OR1; NR1R2 or has one of the significances given for R1; and R5 has one of the significances given for R1, in free form or in salt form for preventing or treating disorders or diseases mediated by interactions between chemokine receptors and their ligands.
A compound of formula I
A compound of the formula
Dependencies are inferred from the claim text.